In a clinical trial of advanced NSCLC with BRAF V600E mutations, the combination of BRAF and MEK inhibitors (dabrafenib and trametinib) had a 64% overall response rate (ORR) in formerly untreated patients (21). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.